Rezulin Postmarketing Safety Data To Be Evaluated By Advisory Committee
Executive Summary
Postmarketing safety and efficacy data of Warner-Lambert's antidiabetic Rezulin will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee March 26.